These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 27475264)

  • 21. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder.
    Drew DS; Muhammed K; Baig F; Kelly M; Saleh Y; Sarangmat N; Okai D; Hu M; Manohar S; Husain M
    Brain; 2020 Aug; 143(8):2502-2518. PubMed ID: 32761061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic gambling in patients with Parkinson's disease.
    Gschwandtner U; Aston J; Renaud S; Fuhr P
    Clin Neuropharmacol; 2001; 24(3):170-2. PubMed ID: 11391129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision making in Parkinson's disease: An analysis of the studies using the Iowa Gambling Task.
    Colautti L; Iannello P; Silveri MC; Antonietti A
    Eur J Neurosci; 2021 Nov; 54(10):7513-7549. PubMed ID: 34655122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease.
    McCoy B; Jahfari S; Engels G; Knapen T; Theeuwes J
    Brain; 2019 Nov; 142(11):3605-3620. PubMed ID: 31603493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor loop dysfunction causes impaired cognitive sequencing in patients suffering from Parkinson's disease.
    Schönberger AR; Hagelweide K; Pelzer EA; Fink GR; Schubotz RI
    Neuropsychologia; 2015 Oct; 77():409-20. PubMed ID: 26382750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iowa Gambling Task Performance in Parkinson Disease Patients with Impulse Control Disorders.
    Biars JW; Johnson NL; Nespeca M; Busch RM; Kubu CS; Floden DP
    Arch Clin Neuropsychol; 2019 May; 34(3):310-318. PubMed ID: 29718062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control.
    Willemssen R; Falkenstein M; Schwarz M; Müller T; Beste C
    Neurobiol Aging; 2011 Feb; 32(2):327-35. PubMed ID: 19269061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decision-making.
    Angioletti L; Siri C; Meucci N; Pezzoli G; Balconi M
    Eur J Neurosci; 2019 Aug; 50(3):2392-2400. PubMed ID: 29888425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological gambling in Parkinson's disease: disease related or drug related?
    Calandrella D; Antonini A
    Expert Rev Neurother; 2011 Jun; 11(6):809-14. PubMed ID: 21651329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease.
    Cools R; Tichelaar JG; Helmich RCG; Bloem BR; Esselink RAJ; Smulders K; Timmer MHM
    Prog Brain Res; 2022; 269(1):309-343. PubMed ID: 35248200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
    van Nuland AJ; Helmich RC; Dirkx MF; Zach H; Toni I; Cools R; den Ouden HEM
    Brain; 2020 Dec; 143(11):3422-3434. PubMed ID: 33147621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease.
    Le Heron C; Plant O; Manohar S; Ang YS; Jackson M; Lennox G; Hu MT; Husain M
    Brain; 2018 May; 141(5):1455-1469. PubMed ID: 29672668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.
    Schaeffer E; Berg D
    CNS Drugs; 2017 Jul; 31(7):551-570. PubMed ID: 28643183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
    Bayard S; Cochen De Cock V; Dauvillers Y
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease.
    Eusebio A; Witjas T; Cohen J; Fluchère F; Jouve E; Régis J; Azulay JP
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):868-74. PubMed ID: 23447648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine restores cognitive motivation in Parkinson's disease.
    McGuigan S; Zhou SH; Brosnan MB; Thyagarajan D; Bellgrove MA; Chong TT
    Brain; 2019 Mar; 142(3):719-732. PubMed ID: 30689734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease.
    Cabrini S; Baratti M; Bonfà F; Cabri G; Uber E; Avanzi M
    Neurol Sci; 2009 Aug; 30(4):307-13. PubMed ID: 19513585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault?
    Brusa L; Pavino V; Massimetti MC; Ceravolo R; Stefani S; Stanzione P
    J Neurol Sci; 2016 Jul; 366():167-170. PubMed ID: 27288799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease.
    Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA
    Neuropsychologia; 2004; 42(14):1917-26. PubMed ID: 15381022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease.
    Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
    J Neurophysiol; 2010 Feb; 103(2):942-9. PubMed ID: 20018839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.